Older Adult Patients Use More Aminosalicylate Monotherapy Compared with Younger Patients with Inflammatory Bowel Disease: TARGET-IBD

Edward L. Barnes, John S. Hanson, Miguel D. Regueiro, Sumona Saha, Bruce E. Sands, David T. Rubin, Marla C. Dubinsky, Corey A. Siegel, Derek R. Gazis, Julie M. Crawford, Millie D. Long

Research output: Contribution to journalArticlepeer-review

Abstract

Goal: The goal of this study was to describe medication utilization patterns in older inflammatory bowel disease (IBD) patients. Background: Despite a growing population of older patients with Crohn's disease (CD) and ulcerative colitis (UC), questions remain regarding medication utilization patterns in comparison to younger populations. Materials and Methods: We collected data from the 34 sites in TARGET-IBD, a multicenter, observational cohort. The primary outcome in this study was the IBD-specific therapy utilized among older patients with IBD compared with younger age groups. Therapy use was analyzed using pairwise comparisons and then the odds of IBD-specific therapy use among patients older than age 65 were evaluated using multivariable logistic regression models. Results: We identified 2980 patients with IBD (61% CD). In multivariable analysis, younger patients with UC were significantly less likely to utilize aminosalicylate monotherapy when compared with patients above 65 years [age 18 to 29: adjusted odds ratio (aOR)=0.51, 95% confidence interval (CI): 0.33-0.78]. In patients with CD, younger patients were significantly less likely to use aminosalicylate monotherapy when compared with patients above 65 (greatest difference age 18 to 29: aOR=0.31, 95% CI: 0.18-0.52). Younger patients with CD and UC were significantly more likely to use anti-tumor necrosis factor monotherapy than patients above 65 years (age 18 to 29: aOR=3.87, 95% CI: 2.47-6.06 and aOR=2.68, 95% CI: 1.29-5.58, respectively). Conclusions: Older patients with IBD demonstrate significant differences in medication utilization, including more aminosalicylate monotherapy and less anti-tumor necrosis factor monotherapy compared with younger age groups. Given the aging population in the United States, these utilization patterns may have long-term implications for disease control.

Original languageEnglish
Pages (from-to)529-535
Number of pages7
JournalJournal of Clinical Gastroenterology
Volume56
Issue number6
DOIs
StatePublished - 1 Jul 2022

Keywords

  • Crohn's disease
  • inflammatory bowel disease
  • older patients
  • ulcerative colitis

Fingerprint

Dive into the research topics of 'Older Adult Patients Use More Aminosalicylate Monotherapy Compared with Younger Patients with Inflammatory Bowel Disease: TARGET-IBD'. Together they form a unique fingerprint.

Cite this